Cellectar Biosciences — Third Quarter 2026 Earnings Summary

Cellectar Biosciences reported a net loss of $8.0 million for the third quarter of 2026, driven by increased research and development expenses associated with its Phase 3 confirmatory trial for iopofosine I 131. The company presented new efficacy data at the International Workshop for Waldenström Macroglobulinemia showing an 87.5% overall response rate in patients treated immediately after BTK inhibitor therapy. Cellectar remains on track to dose the first patient in its Phase 3 trial in the first quarter of 2027 and plans to file for accelerated approval with the FDA in the first half of 2027. Additionally, the company initiated a Phase 1b dosimetry trial and highlighted a case study of a diffuse large B-cell lymphoma patient who maintained a complete response for over eight years following treatment.